!-- notag -->
!-- notag -->
!-- notag -->
Press Releases - 2021 - Sanofi
Worldwide presence
English
English
français
Media
MMMM D, YYYY
Press Releases 2021
Home
Media
Press releases
2021
Press Releases - 2021
Facebook
Twitter
LinkedIn
Download the PDF version
2021-12-21
MMMM DD YYYY
Press releases
Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics
Download the PDF version
2021-12-16
MMMM DD YYYY
Press releases
Press Release: Gilles SCHNEPP takes over as Chairman of the Appointments, Governance and CSR Committee of Sanofi
Download the PDF version
2021-12-15
MMMM DD YYYY
Press releases
Sanofi and GSK announce positive preliminary booster data for their COVID-19 vaccine candidate and continuation of Phase 3 trial per independent Monitoring Board recommendation
Download the PDF version
2021-12-14
MMMM DD YYYY
Press releases
Data from two Phase 3 studies demonstrating fitusiran significantly reduced bleeds in people with hemophilia A or B, with or without inhibitors, were featured at ASH’s plenary and late-breaking sessions
Download the PDF version
2021-12-13
MMMM DD YYYY
Press releases
Positive Phase 3 Dupixent® (dupilumab) data in children 6 months to 5 years with moderate-to-severe atopic dermatitis featured in RAD 2021 late-breaking session
Download the PDF version
2021-12-11
MMMM DD YYYY
Press releases
Sarclisa® (isatuximab) trial is first Phase 3 study to meet primary endpoint of minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma
Download the PDF version
2021-12-08
MMMM DD YYYY
Press releases
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
Download the PDF version
2021-12-06
MMMM DD YYYY
Press releases
EMA accepts regulatory submission for olipudase alfa, the first potential therapy for ASMD
Download the PDF version
2021-12-01
MMMM DD YYYY
Press releases
Vaccines Investor Event: Sanofi reiterates confidence in strong growth outlook and showcases pipeline of innovative vaccine candidates
Download the PDF version
2021-12-01
MMMM DD YYYY
Press releases
Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy
Download the PDF version
2021-11-18
MMMM DD YYYY
Press releases
Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline
Download the PDF version
2021-11-12
MMMM DD YYYY
Press releases
Sanofi announces results of CHMP re-examination of the New Active Substance status for avalglucosidase alfa, a potential new standard of care for the treatment of Pompe disease
Download the PDF version
2021-11-09
MMMM DD YYYY
Press releases
Sanofi completes acquisition of Kadmon
Download the PDF version
2021-11-04
MMMM DD YYYY
Press releases
New data in blood cancers, hemophilia, and other hematological disorders to be presented at ASH 2021
Download the PDF version
2021-10-28
MMMM DD YYYY
Press releases
Sanofi: Strong Q3 performance drives guidance upgrade to around 14% business EPS growth at CER(1)
Download the PDF version
2021-10-25
MMMM DD YYYY
Press releases
Second Dupixent® (dupilumab) Phase 3 eosinophilic esophagitis trial to demonstrate significant disease improvements, underscoring role of type 2 inflammation in this complex disease
Download the PDF version
2021-10-22
MMMM DD YYYY
Press releases
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Download the PDF version
2021-10-20
MMMM DD YYYY
Press releases
FDA expands approval of Dupixent® (dupilumab) to include children aged 6 to 11 years with moderate-to-severe asthma
Download the PDF version
2021-10-13
MMMM DD YYYY
Press releases
New long-term data reinforcing promising safety and efficacy profile of brain-penetrant tolebrutinib presented at ECTRIMS 2021
Download the PDF version
2021-10-12
MMMM DD YYYY
Press releases
Update from Sanofi regarding Kevzara® (sarilumab): Supply constraints anticipated until early 2022
Download the PDF version
2021-10-07
MMMM DD YYYY
Press releases
Sanofi: Positive results from the first study of high-dose influenza vaccine with a COVID-19 mRNA booster support co-administration recommendations
Download the PDF version
2021-09-30
MMMM DD YYYY
Press releases
New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis
Download the PDF version
2021-09-28
MMMM DD YYYY
Press releases
Sanofi to focus its COVID-19 development efforts on the recombinant vaccine candidate
Download the PDF version
2021-09-28
MMMM DD YYYY
Press releases
Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate
Download the PDF version
2021-09-27
MMMM DD YYYY
Press releases
New research presented at IDWeek 2021 reinforces Sanofi’s robust vaccines pipeline and commitment to advancing public health protection
Download the PDF version
2021-09-24
MMMM DD YYYY
Press releases
Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes
Download the PDF version
2021-09-21
MMMM DD YYYY
Press releases
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
Download the PDF version
2021-09-19
MMMM DD YYYY
Press releases
ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Download the PDF version
2021-09-14
MMMM DD YYYY
Press releases
Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics
Download the PDF version
2021-09-09
MMMM DD YYYY
Press releases
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
Download the PDF version
2021-09-08
MMMM DD YYYY
Press releases
Sanofi to acquire Kadmon to further strengthen growth of transplant business
Download the PDF version
2021-09-03
MMMM DD YYYY
Press releases
Dupixent® (dupilumab) efficacy and quality of life data in asthma patients across multiple age groups to be presented at 2021 ERS international congress
Download the PDF version
2021-08-30
MMMM DD YYYY
Press releases
Dupixent® (dupilumab) pivotal trial meets all primary and secondary endpoints becoming first biologic medicine to significantly reduce signs and symptoms of moderate-to-severe atopic dermatitis in children as young as 6 months
Download the PDF version
2021-08-06
MMMM DD YYYY
Press releases
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
21-08-05_Libtayo_ENG_v2
2021-08-05
MMMM DD YYYY
Press releases
Phase 3 trial of Libtayo® (cemiplimab) combined with chemotherapy stopped early due to significant improvement in overall survival in patients with first-line advanced non-small cell lung cancer
Download the PDF version
2021-08-03
MMMM DD YYYY
Press releases
Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
Download the PDF version
2021-07-29
MMMM DD YYYY
Press releases
Online availability of Sanofi’s half-year financial report for 2021
Download the PDF version
2021-07-29
MMMM DD YYYY
Press releases
Sanofi appoints new leaders to Executive Committee and announces future Chair of EUROAPI
Press_Release_Q2_2021_EN
2021-07-29
MMMM DD YYYY
Press releases
Sales growth accelerated - Full-year guidance raised
Download the PDF version
2021-07-29
MMMM DD YYYY
Press releases
Dupixent® (dupilumab) significantly improved itch and hives in patients with chronic spontaneous urticaria, a step forward in demonstrating the role of type 2 inflammation in these patients
Download the PDF version
2021-07-27
MMMM DD YYYY
Press releases
Sanofi provides update on avalglucosidase alfa EU submission for patients with Pompe Disease
Download the PDF version
2021-07-22
MMMM DD YYYY
Press releases
Sanofi continues streamlining of established products with sale of dental care brands to Septodont
Download the PDF version
2021-07-19
MMMM DD YYYY
Press releases
US FDA approves fexinidazole as the first all-oral treatment for sleeping sickness
Download the PDF version
2021-07-15
MMMM DD YYYY
Press releases
Conversion of Kiadis to a private limited liability company postponed until completion of statutory buy-out proceedings
Download the PDF version
2021-07-13
MMMM DD YYYY
Press releases
Sanofi streamlines Consumer Healthcare portfolio in Latin America with divestiture of eight brands to Hypera Pharma
Download the PDF version
2021-07-13
MMMM DD YYYY
Press releases
Sanofi announces Paris 2024 Premium partnership for the Olympic and Paralympic Games in Paris
Download the PDF version
2021-07-10
MMMM DD YYYY
Press releases
MenQuadfi® demonstrates superior immune response against serogroup C meningococcal disease in toddlers
Download the PDF version
2021-07-02
MMMM DD YYYY
Press releases
Sanofi highlights scientific innovations in the field of rare blood disorders at ISTH 2021
Download the PDF version
2021-06-29
MMMM DD YYYY
Press releases
Sanofi launches dedicated vaccines mRNA Center of Excellence
Download the PDF version
2021-06-28
MMMM DD YYYY
Press releases
New Soliqua® data shows improved blood sugar control without weight gain versus premixed insulin
Download the PDF version
2021-06-28
MMMM DD YYYY
Press releases
Nirsevimab shows positive topline results in RSV Phase 2/3 MEDLEY trial
Download the PDF version
2021-06-28
MMMM DD YYYY
Press releases
Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA
Download the PDF version
2021-06-28
MMMM DD YYYY
Press releases
Dupixent® (dupilumab) SmPC updated with long-term data reinforcing well-established safety profile in adults with moderate-to-severe atopic dermatitis
Download the PDF version
2021-06-25
MMMM DD YYYY
Press releases
Sanofi: Availability of the Q2 2021 Memorandum for modelling purposes
Download the PDF version
2021-06-25
MMMM DD YYYY
Press releases
Sanofi: Libtayo® (cemiplimab) approved by the European Commission as the first immunotherapy indicated for patients with advanced basal cell carcinoma
Download the PDF version
2021-06-25
MMMM DD YYYY
Press releases
Sanofi: Libtayo® (cemiplimab) approved by the European Commission for first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression
Download the PDF version
2021-06-22
MMMM DD YYYY
Press releases
Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine
Download the PDF version
2021-06-18
MMMM DD YYYY
Press releases
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
Download the PDF version
2021-06-11
MMMM DD YYYY
Press releases
New pivotal data at EHA 2021 reinforces sutimlimab as a first-in-class investigational C1s inhibitor with the potential to be the first approved treatment for hemolysis in people with CAD, a serious and chronic autoimmune hemolytic anemia
Download the PDF version
2021-06-11
MMMM DD YYYY
Press releases
Sanofi provides update on Aubagio® (teriflunomide) submission for children and adolescents with relapsing-remitting multiple sclerosis in the U.S.
Download the PDF version
2021-06-07
MMMM DD YYYY
Press releases
Sanofi launches its new global employee share ownership plan
Download the PDF version
2021-06-04
MMMM DD YYYY
Press releases
Sanofi partnering with leading academic cooperative groups to study amcenestrant in the adjuvant setting for patients with estrogen receptor positive breast cancer
Download the PDF version
2021-06-03
MMMM DD YYYY
Press releases
Sanofi launches €3 million Planet Mobilization fund to support employees’ environmental projects
Download the PDF version
2021-06-01
MMMM DD YYYY
Press releases
Sanofi provides update on venglustat clinical program
Download the PDF version
2021-05-27
MMMM DD YYYY
Press releases
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate
Download the PDF version
2021-05-24
MMMM DD YYYY
Press releases
Libtayo® (cemiplimab) receives positive CHMP opinion for the treatment in Europe of two advanced cancers
Download the PDF version
2021-05-19
MMMM DD YYYY
Press releases
Sanofi to showcase data from its transformative oncology pipeline at 2021 ASCO Meeting
Download the PDF version
2021-05-19
MMMM DD YYYY
Press releases
Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer
Download the PDF version
2021-05-17
MMMM DD YYYY
Press releases
Pivotal data at ATS 2021 show Dupixent® (dupilumab) significantly reduced asthma attacks and improved lung function in children
Download the PDF version
2021-05-17
MMMM DD YYYY
Press releases
Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
Download the PDF version
2021-05-12
MMMM DD YYYY
Press releases
New data to be featured at EHA 2021 Congress highlight Sanofi’s ongoing commitment to rare blood disorders
Download the PDF version
2021-05-12
MMMM DD YYYY
Press releases
Positive Phase 3 Libtayo® (cemiplimab) results in advanced cervical cancer presented at ESMO Virtual Plenary
Download the PDF version
2021-05-06
MMMM DD YYYY
Press releases
Sanofi establishes three-year collaboration with Stanford Medicine to accelerate immunology research
Download the PDF version
2021-04-30
MMMM DD YYYY
Press releases
Annual General Meeting of April 30, 2021
Download the PDF version
2021-04-29
MMMM DD YYYY
Press releases
Final results of the Offer for Kiadis: 97.39% of Kiadis Shares in total committed under the Offer
Download the PDF version
2021-04-28
MMMM DD YYYY
Press releases
Sanofi continued its growth trajectory. Strong increase in Q1 2021 business EPS(1) at CER
Download the PDF version
2021-04-26
MMMM DD YYYY
Press releases
Delisting of Kiadis will be effective on 25 May 2021
Download the PDF version
2021-04-26
MMMM DD YYYY
Press releases
Sanofi to help manufacture Moderna COVID-19 vaccine, supporting global supply demands
Download the PDF version
2021-04-26
MMMM DD YYYY
Press releases
Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial
Download the PDF version
2021-04-23
MMMM DD YYYY
Press releases
New Dupixent® (dupilumab) analyses reinforce long-term safety and efficacy profile in patients with atopic dermatitis as young as 6 years
Download the PDF version
2021-04-19
MMMM DD YYYY
Press releases
European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
Download the PDF version
2021-04-16
MMMM DD YYYY
Press releases
Sanofi completes Kiadis acquisition
Download the PDF version
2021-04-13
MMMM DD YYYY
Press releases
Sanofi declares the offer for Kiadis unconditional
Download the PDF version
2021-04-12
MMMM DD YYYY
Press releases
Sanofi to invest in a leading-edge production site in Singapore; continues to strengthen its vaccines manufacturing capacities
FINAL Tidal Press Release 040921-IP Edits
2021-04-09
MMMM DD YYYY
Press releases
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
Download the PDF version
2021-04-09
MMMM DD YYYY
Press releases
Sanofi completes Kymab acquisition
Download the PDF version
2021-04-09
MMMM DD YYYY
Press releases
Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2
Download the PDF version
2021-04-07
MMMM DD YYYY
Press releases
Positive results from the sutimlimab pivotal trial for people with cold agglutinin disease published in New England Journal of Medicine
Download the PDF version
2021-04-07
MMMM DD YYYY
Press releases
Sanofi expands its social commitments, creates nonprofit unit to provide poorest countries with access to essential medicines
Download the PDF version
2021-03-31
MMMM DD YYYY
Press releases
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
Download the PDF version
2021-03-31
MMMM DD YYYY
Press releases
Sanofi to build new facility in Canada to increase global availability of high-dose influenza vaccine
Download the PDF version
2021-03-23
MMMM DD YYYY
Press releases
Sanofi continues streamlining of established products with sale of anti-inflammatory drugs to Fidia Farmaceutici
Download the PDF version
2021-03-19
MMMM DD YYYY
Press releases
Availability of the Q1 2021 Memorandum for modelling purposes
Download the PDF version
2021-03-15
MMMM DD YYYY
Press releases
Phase 3 trial of Libtayo® (cemiplimab) monotherapy in advanced cervical cancer stopped early for positive result on overall survival
Download the PDF version
2021-03-12
MMMM DD YYYY
Press releases
Sanofi and Translate Bio initiate Phase 1/2 clinical trial of mRNA COVID-19 vaccine candidate
Download the PDF version
2021-03-04
MMMM DD YYYY
Press releases
Filing of the 2020 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report
Download the PDF version
2021-03-04
MMMM DD YYYY
Press releases
FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma
PR Board ENG - 03032021 final
2021-03-03
MMMM DD YYYY
Press releases
Sanofi’s Board of Directors proposes the appointment of Christian Brandts and Barbara Lavernos as Board Members
Download the PDF version
2021-02-26
MMMM DD YYYY
Press releases
CHMP recommends approval of Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for the treatment of relapsed multiple myeloma
Download the PDF version
2021-02-22
MMMM DD YYYY
Press releases
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Download the PDF version
2021-02-22
MMMM DD YYYY
Press releases
Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
20200222-Sanofi-statement-EN
2021-02-22
MMMM DD YYYY
Press releases
Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
Download the PDF version
2021-02-18
MMMM DD YYYY
Press releases
Efanesoctocog alfa granted FDA Fast Track Designation for treatment of hemophilia A
Download the PDF version
2021-02-12
MMMM DD YYYY
Press releases
The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
Download the PDF version
2021-02-12
MMMM DD YYYY
Press releases
Sanofi launches recommended cash offer for all shares in Kiadis
Download the PDF version
2021-02-12
MMMM DD YYYY
Press releases
Offer Memorandum for All Outstanding Shares of Kiadis Pharma N.V.
Download the PDF version
2021-02-09
MMMM DD YYYY
Press releases
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
Download the PDF version
2021-02-09
MMMM DD YYYY
Press releases
New indication for Plavix® (clopidogrel) now approved in the European Union
Download the PDF version
2021-02-05
MMMM DD YYYY
Press releases
Sanofi presents amended protocols in fitusiran clinical studies at EAHAD 2021
Download the PDF version
2021-02-05
MMMM DD YYYY
Press releases
Capital Markets Day 2021: Sanofi progresses on its strategy to drive growth across its businesses and innovation with emerging leadership in immunology
Download the PDF version
2021-02-05
MMMM DD YYYY
Press releases
Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER
Download the PDF version
2021-02-02
MMMM DD YYYY
Press releases
Kiadis shareholders give irrevocable commitment to tender 36.6% of the shares under the offer by Sanofi
Download the PDF version
2021-02-02
MMMM DD YYYY
Press releases
Data presented at WORLDSymposiumTM reinforces robust rare disease pipeline and highlights additional clinical data for investigational avalglucosidase alfa in Pompe disease
Download the PDF version
2021-02-01
MMMM DD YYYY
Press releases
New Dupixent® (dupilumab) data showcasing improvements across four type 2 inflammatory diseases to be presented at 2021 AAAAI Annual Meeting
Sanofi ENG FINAL
2021-01-27
MMMM DD YYYY
Press releases
Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine to help address public health needs
Download the PDF version
2021-01-12
MMMM DD YYYY
Press releases
SANOFI unveils EUROAPI as the name of the new industry leading European API* company and appoints Karl Rotthier as its future Chief Executive Officer
Download the PDF version
2021-01-11
MMMM DD YYYY
Press releases
Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
!-- notag -->